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In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have
been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D
(DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective
study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs
those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-
like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice. From a
population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or compar-
ator glucose-lowering medications (GLMs), 6751 of whom had a follow-up examination. At
baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher
glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM
use, but the clinical profile of patients receiving dapagliflozin changed during the study period.
Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by
3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs.
This real-world study shows an initial channelling of dapagliflozin to difficult-to-treat patients.
Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body
weight and blood pressure that were in line with findings from RCTs.
KEYWORDS
cohort study, dapagliflozin, glycaemic control, observational study, type 2 diabetes, weight
control
1 | INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT2) inhibitors exert a variety of
favourable glycaemic and extra-glycaemic effects1; in phase III ran-
domized controlled trials (RCTs), SGLT2 inhibitors lowered glycated
haemoglobin (HbA1c) concentration by ~0.5% to 0.7%, body weight
by 2 to 3 kg, and blood pressure by 3 to 4 mm Hg in people with
type 2 diabetes (T2D).2,3 Although RCTs deliver the best evidence for
clinical decisions, they have limited external transferability.4 Real-
world retrospective studies using routinely accumulated clinical data
are regaining interest for their ability to collect large representative
datasets in a relatively short time. These studies are subject to
channelling bias (or confounding by indication),5 especially for newly
marketed drugs.6 This can be addressed using strategies of propen-
sity score matching (PSM).7 When a sufficient overlap between
patient groups exists,8 PSM can generate quasi-experimental compar-
isons that make retrospective studies closer to RCTs. For instance,
2 RCTs indicate that SGLT2 inhibitors improve cardiovascular out-
comes in patients with T2D and high risk for or established cardio-
vascular disease9,10 and 2 retrospective studies on administrative
databases have confirmed these findings in broader T2D patient
populations.11,12
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The DARWIN-T2D study was a multicentre Italian retrospective
study, designed to evaluate the use and effectiveness of dapagliflozin,
the first-in-class SGLT2 inhibitor in Italy, compared with other
glucose-lowering medications (GLMs) in routine clinical practice.13 In
the present study, we report data on baseline clinical characteristics
with their temporal trends, along with an initial assessment of
effectiveness.
2 | MATERIALS AND METHODS
We have previously published a detailed description of the design
of the present study13 and an expanded Methods section can be
found in the Supporting Information. Briefly, the DARWIN-T2D
study was a multicentre nationwide retrospective study, designed
to evaluate the baseline clinical characteristics and the change in
glycaemic and extra-glycaemic effectiveness variables in patients
initiated on dapagliflozin vs patients initiated on dipeptidyl
peptidase-4 (DPP-4) inhibitors, gliclazide, or glucagon-like peptide-
1 receptor agonists (GLP-1RAs), in Italian diabetes outpatient
clinics. The study flowchart is shown in Figure S1 in Appendix S1.
Automated software retrospectively extracted data from the same
electronic chart system at all centres.
2.1 | Statistical analysis
Continuous variables are presented as mean  SD, and categorical
variables are expressed as percentages. Normality was checked using
the Kolmogorov–Smirnov test and non-normal variables were log-
transformed. Comparison between the 2 groups was performed using
the two-tailed unpaired Student's t test or χ2 test. Adjusting for mul-
tiple testing was performed using the Benjamini–Hochberg proce-
dure. The two-tailed paired Student's t test was used to compare
data collected at follow-up with those collected at baseline. P values
<.05 were taken to indicate statistical significance.
3 | RESULTS
3.1 | Baseline clinical characteristics
The study collected data from 46 Italian diabetes specialist outpatient
clinics, for a total background population of 281 217 patients with
T2D. For the purpose of the present analysis, we extracted detailed
information on 17 285 patients who initiated dapagliflozin (n = 2484),
a DPP-4 inhibitor (n = 6594: sitagliptin 57.2%; alogliptin 19.7%; vilda-
gliptin 19.6%; saxagliptin 3.5%), gliclazide (n = 5960), or a long-acting
GLP-1RA (n = 2247: liraglutide 73.3%; exenatide extended release
26.7%) between March 15, 2015 and December 31, 2016.
The baseline clinical characteristics of patients in the 4 groups
are shown in Table S1 in Appendix S1. Significant differences among
groups were detected for most variables: patients initiated on dapa-
gliflozin were younger, had longer diabetes duration and higher fast-
ing plasma glucose level, HbA1c level and blood pressure than
patients in the other 3 groups and were more obese than patients ini-
tiated on DPP-4 inhibitors or gliclazide, but less obese than patients
initiated on a GLP-1RA. The baseline lipid profile was slightly but sig-
nificantly worse in the dapagliflozin vs the DPP-4 inhibitor and glicla-
zide groups, but not when compared with the GLP-1RA group. The
frequency of microangiopathy at baseline was higher in patients initi-
ated on dapagliflozin than in the other 3 groups, whereas the fre-
quency of macroangiopathy was lower in the dapagliflozin than in the
DPP-4 inhibitor and gliclazide groups.
Metformin and insulin use were more common in the dapagliflo-
zin group than in the other 3 groups, at the time of prescription of
the new drugs and in the previous prescription. More than half of
patients receiving dapagliflozin were insulin-treated, about half of
whom were on basal-bolus insulin. The historical therapeutic regimen
was also more complex in the dapagliflozin than in the other groups.
All concomitant cardiovascular medications were less frequent among
dapagliflozin users than in the control groups.
Heterogeneity arising from the centre effect, geographical loca-
tion, and temporal trends are described in the Supporting Information
(Table S2, S3, Figures S2, S3 in Appendix S1).
3.2 | Analyses of effectiveness
Changes in glycaemic and extra-glycaemic effectiveness variables
were calculated for patients having a follow-up visit 3 to 12 months
after baseline and still being on drug. Of the 17 285 patients evalu-
ated at baseline, n = 6751 (39.1%) had a follow-up visit: n = 830
(33.4%) for dapagliflozin, n = 2999 (45.5%) for DPP-4 inhibitors,
n = 2111 (35.4%) for gliclazide, and n = 811 (36.1%) for GLP-1RAs
(Table 1, Figure 1).
Patients initiated on dapagliflozin, after an average of 168 days
(5.5 months), showed significant improvements in fasting plasma glu-
cose (−28.2 mg/dL), HbA1c (−0.7%), body weight (−2.7 kg), systolic
blood pressure (−3.0 mm Hg), diastolic blood pressure (−1.3 mm Hg),
total cholesterol (−3.5 mg/dL), HDL cholesterol (+1.6 mg/dL) and tri-
glycerides (−15.9 mg/dL), with no change in LDL cholesterol. For
patients initiating dapagliflozin on a background of insulin therapy,
HbA1c significantly declined by 0.8% (from 9.1% to 8.3%) and body
weight significantly declined by 2.2 kg (from 93.2 to 91.0 kg).
Patients initiated on a DPP-4 inhibitor, after an average 185 days
(6.1 months), showed significant improvements in fasting plasma glu-
cose (−11.5 mg/dL), HbA1c (−0.6%), body weight (−0.5 kg), total cho-
lesterol (−5.4 mg/dL), triglycerides (−8.1 mg/dL) and LDL cholesterol
(−4.2 mg/dL).
Patients initiated on gliclazide, after an average of 185 days
(6.1 months), showed significant improvements in fasting plasma glu-
cose (−14.8 mg/dL), HbA1c (−0.6%), total cholesterol (−8.0 mg/dL),
triglyceride (−12.9 mg/dL) and LDL cholesterol (−5.5 mg/dL).
Patients initiated on a GLP-1RA, after an average of 169 days
(5.6 months), showed significant improvements in fasting plasma glu-
cose (−17.2 mg/dL), HbA1c (−0.6%), body weight (−2.4 kg), total cho-
lesterol (−11.6 mg/dL) and LDL cholesterol (−10.1 mg/dL).
The percentage of patients meeting the composite endpoint of
simultaneous HbA1c and body weight reduction was 56.9% for dapa-
gliflozin, 40.5% for DPP-4 inhibitors, 28.7% for gliclazide, and 56.2%
for GLP-1RAs (Figure S4 in Appendix S1). The corresponding percent-
ages for the combined endpoint of simultaneous HbA1c, body weight
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and SBP reductions were 31.5%, 18.2%, 12.3% and 29.7%,
respectively.
For each group, we estimated the expected improvement in car-
diovascular risk using the UK Prospective Diabetes Study risk
engine.14 Patients initiated on dapagliflozin showed the most consis-
tent and significant reduction in the estimated 10-year risk of coro-
nary heart disease, fatal coronary heart disease, stroke and fatal
stroke (Table S4 in Appendix S1).
Results of PSM are described in the Supporting Information.
Common support between the dapagliflozin and comparator groups
was very low (Figure S5 in Appendix S1) and the conditions for com-
paring matched cohorts were precarious (Figure S6 in Appendix S1);
therefore, outcome analysis after PSM was not performed.
4 | DISCUSSION
The DARWIN-T2D study was a large retrospective study using clini-
cal data routinely accumulated in electronic charts, involving 17 285
patients, of whom 6751 underwent a follow-up examination. The
comparison of baseline characteristics showed statistically significant
and clinically meaningful differences in most variables between
patients who started dapagliflozin and those who started a compara-
tor. This was expected from an individualized therapy approach, but
the HbA1c divide among groups was striking. A baseline HbA1c value
of 8.7% reflects that dapagliflozin was being preferentially used in
patients with moderately to severely uncontrolled diabetes. The rea-
son for this channelling is probably 2-fold. First, incretin-based thera-
pies were reimbursed by the Italian Healthcare System only if
initiated in patients with an HbA1c between 7.5% and 9.0%, whereas
such a limitation was not imposed on SGLT2 inhibitors. Dapagliflozin
was reimbursed only in association with metformin and/or insulin
(including the basal-bolus regimen), whereas incretin-based therapies
could be reimbursed with multiple combinations of GLMs but not
with basal-bolus insulin, and gliclazide had no reimbursement limita-
tions. These different criteria were responsible for enriching insulin
therapy among patients initiating dapagliflozin. The high baseline
HbA1c and the more frequent use of previous GLMs suggests that
many patients initiating dapagliflozin were poor responders to other
GLM classes. Second, newly marketed drugs are initially tested on
the most difficult-to-treat patients, whereas the peculiar characteris-
tics of patients initiating a new drug are expected to mitigate over
time when the new drug becomes more established. A time-trend
analysis showed that the overall differences in clinical characteristics
at the time patients initiated dapagliflozin vs other treatments were
tapering over time, indicating that dapagliflozin was being progres-
sively used in less severe cases.
The analysis of effectiveness was based on 6751 patients still on
drug at follow-up, about 6 months after baseline. The within-group
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FIGURE 1 Within-group analysis of effectiveness. For A, glycated haemoglogin (HbA1c), B, body weight and C, systolic blood pressure, panels
show baseline and follow-up values, along with changes from baseline (right panels). Numbers on top of columns indicate the corresponding
values. Numbers between brackets indicates the number of available measures for each outcome. *P < .05 vs baseline. DPP-4i, dipeptidyl
peptidase-4 inhibitor; Dapa, dapagliflozin; GLP-1RA, glucagon-like peptide-1 receptor agonist; SBP, systolic blood pressure
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analysis in the total cohort showed improvements in HbA1c (−0.7%),
FPG (−28.2 mg/dL), body weight (−2.7 kg) and systolic blood pressure
(−3.0 mm Hg) after initiation of dapagliflozin that were consistent
with findings from phase III RCTs.2,3 A benefit for lipid profile was
also observed, confirming the increase in HDL cholesterol and reduc-
tion of triglycerides seen in RCTs,15 but with no significant increase
in LDL cholesterol. Among patients initiating dapagliflozin on a back-
ground of insulin therapy, HbA1c and body weight declined more
than in the corresponding RCTs.16 Effectiveness in patients initiated
on DPP-4 inhibitors, gliclazide, or a GLP-1RA was also well within the
range expected from RCTs.17 Cardiovascular risk estimated using the
UK Prospective Diabetes Study risk engine,14 improved with all treat-
ments, but only dapagliflozin therapy was associated with a signifi-
cant reduction in the projected risk of all the 4 endpoints, because of
simultaneous improvements in glucose, body weight, blood pressure
and lipids.
Between-group comparisons of effectiveness were hampered by
massive differences in baseline clinical characteristics that could not
be overcome by PSM. Further analyses will be performed on the
DARWIN-T2D database and its follow-up extension to provide more
information on comparative effectiveness.
The present study has all the limitations inherent to its retrospec-
tive nature, including patient heterogeneity, risk of inverse causality,
and concerns with regard to data quality and missingness. Impor-
tantly, the DARWIN-T2D database is not yet linked with administra-
tive registries and data on hard cardiovascular endpoints are not
available. Major strengths of the DARWIN-T2D study include the
large sample size with nationwide distribution, the extensive patient
characterization and, above all, the automatic data extraction from
the same electronic chart, which granted uniform data coding and
limited reporting errors.
In conclusion, during the first 21 months after marketing authori-
zation approval in Italian routine clinical practice, dapagliflozin was
prescribed to the most difficult-to-treat patients, many of whom
were poor responders to previous GLMs and > 50% were on insulin.
A “launch effect” and differential reimbursement criteria were
responsible for this massive channelling, but the scenario is progres-
sively changing. Nonetheless, even in difficult-to-treat patients, the
effectiveness of dapagliflozin with regard to glycaemic and extra-
glycaemic endpoints was similar to results obtained in RCTs and
> 50% of patients experienced a simultaneous reduction in HbA1c
and body weight.
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Agostino Consoli and Gloria Formoso (Dipartimento di Medicina e
Scienze dell'Invecchiamento - Università Degli studi G. D'Annunzio di
Chieti-Pescara); Giovanni Grossi (Ospedale San Francesco di Paola -
Azienda Sanitaria Provinciale di Cosenza); Achiropita Pucci (Azienda
Sanitaria Provinciale di Cosenza); Giorgio Sesti and Francesco
Andreozzi (Azienda Ospedaliero Universitaria di Catanzaro); Giuseppe
Capobianco (Azienda Sanitaria Locale Napoli 2 Nord); Adriano Gatti
(Ospedale San Gennaro dei Poveri - Azienda Sanitaria Locale Napoli
1 Centro); Riccardo Bonadonna, Ivana Zavaroni and Alessandra Dei
Cas (Azienda Ospedaliero Universitaria di Parma); Giuseppe Felace
(Ospedale di Spilimbergo - Azienda per l'Assistenza Sanitaria n.5 Friuli
Occidentale); Patrizia Li Volsi (Ospedale di Pordenone - Azienda per
l'Assistenza Sanitaria n.5 Friuli Occidentale); Raffaella Buzzetti and
Gaetano Leto (Ospedale Santa Maria Goretti - Azienda Sanitaria
Locale di Latina); Gian Pio Sorice (Fondazione Policlinico Universitario
A. Gemelli, Roma); Paola D'Angelo (Ospedale Sandro Pertini - Azienda
Sanitaria Locale Roma 2); Susanna Morano (Azienda Ospedaliera Uni-
versitaria Policlinico Umberto I, Roma); Antonio Carlo Bossi
(Ospedale di Treviglio - Azienda Socio Sanitaria Territoriale Bergamo
Ovest); Edoardo Duratorre (Ospedale Luini Confalonieri di Luino
Azienda Socio Sanitaria Territoriale Sette Laghi).
Ivano Franzetti (Ospedale Sant'Antonio Abate di Gallarate
Azienda Socio Sanitaria Territoriale Valle Olona); Paola Silvia
Morpurgo (Ospedale Fatebenefratelli - Azienda Socio Sanitaria Terri-
toriale Fatebenefratelli Sacco); Emanuela Orsi (Fondazione IRCCS
Ca’ Granda - Ospedale Maggiore Policlinico di Milano); Fabrizio
Querci (Ospedale Pesenti Fenaroli di Alzano Lombardo - Azienda
Socio Sanitaria Territoriale Bergamo Est); Massimo Boemi† and Fed-
erica D'Angelo (Presidio Ospedaliero di Ricerca INRCA-IRCCS di
Ancona); Massimiliano Petrelli (Azienda Ospedaliero Universitaria
Ospedali Riuniti di Ancona); Gianluca Aimaretti and Ioannis Kara-
mouzis (Azienda Ospedaliero Universitaria Maggiore della Carità di
Novara); Franco Cavalot (Azienda Ospedaliero Universitaria San
Luigi Gonzaga, Orbassano); Giuseppe Saglietti† (Ospedale Madonna
del Popolo di Omegna - Azienda Sanitaria Locale Verbano Cusio
Ossola); Giuliana Cazzetta (Casa della Salute, Ugento - Distretto
Socio Sanitario Gagliano del Capo - Azienda Sanitaria Locale di
Lecce); Silvestre Cervone (Presidio ospedaliero San Marco in Lamis
Distretto Socio Sanitario San Marco in Lamis - Azienda Sanitaria
Locale di Foggia); Eleonora Devangelio (Distretto Socio Sanitario di
Massafra - Azienda Sanitaria Locale di Taranto); Olga Lamacchia
(Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia); Salva-
tore Arena (Ospedale Umberto I – Azienda Sanitaria Provinciale di
Siracusa); Antonino Di Benedetto (Azienda Ospedaliera Universitaria
Policlinico G. Martino di Messina); Lucia Frittitta (Azienda Ospeda-
liera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Cata-
nia); Carla Giordano (Azienda Universitaria Policlinico Paolo
Giaccone di Palermo); Salvatore Piro (Azienda Ospedaliera di Rilievo
Nazionale e di Alta Specializzazione Garibaldi di Catania); Manfredi
Rizzo, Roberta Chianetta and Carlo Mannina (Azienda Universitaria
Policlinico Paolo Giaccone di Palermo); Roberto Anichini (Ospedale
San Jacopo di Pistoia – Azienda USL Toscana Centro); Giuseppe
Penno (Azienda Ospedaliero Universitaria Pisana); Anna Solini
(Azienda Ospedaliera Universitaria Pisana); Bruno Fattor
(Comprensorio Sanitario di Bolzano - Azienda Sanitaria della Provin-
cia Autonoma di Bolzano); Enzo Bonora and Massimo Cigolini
(Azienda Ospedaliero Universitaria Integrata di Verona); Annunziata
Lapolla and Nino Cristiano Chilelli (Complesso Socio Sanitario Ai
Colli - Azienda ULSS n.6 Euganea); Maurizio Poli (Ospedale Giro-
lamo Fracastoro di San Bonifacio - Azienda ULSS n.9 Scaligera);
Natalino Simioni and Vera Frison (Ospedale di Cittadella - Azienda
ULSS n.6 Euganea); Carmela Vinci (Azienda ULSS n.4 Veneto
Orientale).
FADINI ET AL. 1785
ACKNOWLEDGMENTS
We are grateful for the technical support of Alessia Russo, Italian
Diabetes Society.
Conflict of interest
G.P.F. has received grant support, lecture or advisory board fees from
AstraZeneca, Boehringer-Ingelheim, Eli Lilly, NovoNordisk, Sanofi,
Genzyme, Abbott, Novartis and Merck Sharp & Dohme.
A.C. has received consultancy or speaker fees from Abbott,
AstraZeneca, Boehringer-Ingelheim, Bruno Farmaceutici, Janssen,
Eli-Lilly, Merck Sharp & Dohme, Novartis, NovoNordisk, Roche,
Sanofi-Aventis, Servier and Takeda. He has also received research
grants from Eli-Lilly and NovoNordisk. A.G. has received consultancy
or speaker fees from AstraZeneca, Boehringer-Ingelheim, Eli-Lilly,
Merck Sharp & Dohme, Sanofi-Aventis and Takeda. He has also
received a research grant from AstraZeneca. G.S. has received fees
for advisory work or lectures from Servier, Intarcia Therapeutics Inc,
NovoNordisk, Janssen, Boehringer-Ingelheim, Eli Lilly, AstraZeneca,
Merck Sharp & Dohme Italy, Lilly, Sanofi, Novartis, Abbott and
Takeda. A.A. has received research grants, lecture or advisory board
fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-
Ingelheim, Sanofi, Mediolanum, Janssen, NovoNordisk, Lilly, Servier
and Takeda. G.Z., D.B. and I.B. declare no conflict of interest.
Author contributions
Author contributions were as follows: design, data collection and
analysis: G.P.F., G.Z., D.B., I.B., A.C., G.S. and A.A.; manuscript writing:
G.P.F. and A.A.; and manuscript revising for intellectual content: G.Z.,
A.G., A.C. and G.S. All authors approved the final version of the
manuscript.
ORCID
Gian Paolo Fadini http://orcid.org/0000-0002-6510-2097
Angelo Avogaro http://orcid.org/0000-0002-1177-0516
REFERENCES
1. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose
cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabe-
tes. Endocr Rev. 2011;32:515-531.
2. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW,
White WB. Effects of sodium-glucose co-transporter 2 inhibitors on
blood pressure: a systematic review and meta-analysis. J Am Soc
Hypertens. 2014;8:262-275, e269.
3. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glu-
cose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of
randomized clinical trials. Diabetes Obes Metab. 2014;16:457-466.
4. Frieden TR. Evidence for health decision making - beyond random-
ized, controlled trials. N Engl J Med. 2017;377:465-475.
5. Patel A, Billot L. Reality and truth. Balancing the hope and the hype
of real-world evidence. Circulation. 2017;136:260-262.
6. Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S.
Treatment dynamics of newly marketed drugs and implications
for comparative effectiveness research. Value Health. 2013;16:
1054-1062.
7. Austin PC, Laupacis A. A tutorial on methods to estimating clinically
and policy-meaningful measures of treatment effects in prospective
observational studies: a review. Int J Biostat. 2011;7:6.
8. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and
assessing propensity scores. Health Serv Res. 2014;49:1701-1720.
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovas-
cular and renal events in type 2 diabetes. N Engl J Med. 2017;377:
644-657.
10. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular
outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:
2117-2128.
11. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Car-
diovascular outcomes and risks after initiation of a sodium glucose
co-transporter 2 inhibitor: results from the EASEL population-based
cohort study. Circulation. 2017. https://doi.org/10.1161/
CIRCULATIONAHA.117.031227 [Epub ahead of print].
12. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure
and death in patients initiated on sodium-glucose Cotransporter-2
inhibitors versus other glucose-lowering drugs: the CVD-REAL study
(comparative effectiveness of cardiovascular outcomes in new users
of sodium-glucose Cotransporter-2 inhibitors). Circulation. 2017;136:
249-259.
13. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A. Rationale
and design of the DARWIN-T2D (DApagliflozin real world evIdeNce
in type 2 diabetes): a multicenter retrospective nationwide Italian
study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis.
2017;27:1089-1097.
14. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine:
a model for the risk of coronary heart disease in Type II diabetes
(UKPDS 56). Clin Sci (Lond). 2001;101:671-679.
15. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E.
Durability and tolerability of dapagliflozin over 52 weeks as add-on
to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes
Metab. 2015;17:1075-1084.
16. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflo-
zin in patients with type 2 diabetes mellitus receiving high doses of
insulin: a randomized trial. Ann Intern Med. 2012;156:405-415.
17. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin
antidiabetic drugs added to metformin therapy on glycemic control,
weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:
1410-1418.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: Fadini GP, Zatti G, Baldi I, et al. Use
and effectiveness of dapagliflozin in routine clinical practice:
An Italian multicentre retrospective study. Diabetes Obes
Meta. 2018;20:1781–1786. https://doi.org/10.1111/dom.
13280
1786 FADINI ET AL.
